121 results on '"Lin, Jianzhen"'
Search Results
2. Supplementary Table S1-S4. from Alterations in DNA Damage Repair Genes in Primary Liver Cancer
3. Supplementary Figure S1-S3. from Alterations in DNA Damage Repair Genes in Primary Liver Cancer
4. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
5. Comment on: Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm
6. Secure data rate maximization for full-duplex UAV-enabled base station
7. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
8. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
9. Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer
10. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma
11. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
12. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
13. UAV-Assisted Data Rate Maximization Under 3-D Channel Model
14. Mutational spectrum and precision oncology for biliary tract carcinoma
15. Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
16. Amniotic Membrane Extract Protects Islets From Serum-Deprivation Induced Impairments and Improves Islet Transplantation Outcome
17. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma
18. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients
19. Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis
20. Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
21. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
22. Genomics and translational precision oncology for 803 patients with biliary tract cancer.
23. Change in Viability and Function of Pancreatic Islets after Coculture with Mesenchymal Stromal Cells: A Systemic Review and Meta-Analysis
24. BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab
25. Comparison of different kinetic models for dynamic 18F-FDG PET/CT imaging of hepatocellular carcinoma with various, also dual-blood input function
26. Application of the Lung Immune Prognostic Index From Research to Clinical Practice
27. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials
28. Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View
29. Systemic management for patients with hepatobiliary tumors in a multi-dimensional view
30. Unleashing The Potential Of Multiple-Targeted Therapies In Hepatobiliary Cancers: Two Cases, Cocktail Therapy With Nine Molecular Targeted Agents And Long-Lasting Survival
31. CMTTdb: the cancer molecular targeted therapy database
32. Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Focusing on Organ-Specific irAEs and the Critical Role of Steroids
33. Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma
34. Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice
35. Construction and Investigation of a lncRNA-Associated ceRNA Regulatory Network in Cholangiocarcinoma
36. Pentapeptide Protects INS-1 Cells From hIAPP-Mediated Apoptosis by Enhancing Autophagy Through mTOR Pathway
37. Alterations in DNA Damage Repair Genes in Primary Liver Cancer
38. The diagnostic and prognostic role of RhoA in hepatocellular carcinoma
39. Abstract 1700: Alterations of DNA damage repair genes in Chinese primary liver cancer patients and its association with tumor mutation burden
40. Abstract 1700: Alterations of DNA damage repair genes in Chinese primary liver cancer patients and its association with tumor mutation burden
41. Abstract 2250: Combinational markers of neoantigen intratumor heterogeneity and neoantigen burden predict progression-free survival for lenvatinib plus PD-1 blockade in patients with intrahepatic cholangiocarcinoma
42. Abstract 4992: The occurrence of immune-related adverse events indicates better efficacy of immune checkpoint blockade in solid tumors: A systematic review and meta-analysis
43. Abstract 2250: Combinational markers of neoantigen intratumor heterogeneity and neoantigen burden predict progression-free survival for lenvatinib plus PD-1 blockade in patients with intrahepatic cholangiocarcinoma
44. Abstract 4992: The occurrence of immune-related adverse events indicates better efficacy of immune checkpoint blockade in solid tumors: A systematic review and meta-analysis
45. Abstract 3988: Identifying prognostic biomarkers of hepatocellular carcinoma by weighted gene coexpression network analysis
46. Abstract 3988: Identifying prognostic biomarkers of hepatocellular carcinoma by weighted gene coexpression network analysis
47. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
48. Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma
49. The fusion landscape of hepatocellular carcinoma
50. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.